Triplebar, a startup working in food and biopharmaceuticals, has recently secured a substantial $20 million in funding to expand its innovative product portfolio. Led by Synthesis Capital and joined by Essential Capital, Stray Dog Capital, iSelect Fund, and existing investor The Production Board, this funding injection propels Triplebar into an exciting phase of growth and development.
At the forefront of this leap is Triplebar’s Hyper-Throughput™ screening platform, a cutting-edge system that serves as a microprocessor for biology.
The platform integrates hardware, software, biology, and biochemistry to miniaturize and accelerate evolution. Through this technology, Triplebar and its commercial partners are reshaping the landscape of food production and healthcare solutions.
Transforming Food Production
Triplebar’s primary mission is to reduce humanity’s environmental footprint while enhancing the quality of life through superior food and biopharmaceuticals. Leveraging their Hyper-Throughput™ screening platform, Triplebar is developing biological systems to manufacture low-cost, low-footprint animal proteins.
These proteins aim to replace traditional animal sources, offering sustainable and ethical alternatives. By improving the performance of animal cell lines for cellular meat products, Triplebar is contributing to the evolution of the food industry.
Triplebar’s platform enables the discovery of novel therapeutic biologic drug candidates in biopharmaceuticals. These innovations can address critical human health challenges, offering hope for enhanced disease treatment outcomes.
By focusing on validated targets and previously considered ‘undruggable’ targets, Triplebar is pioneering advancements in healthcare solutions.
Strategic Partnerships, Catalysts for Progress
Strategic partnerships amplify Triplebar’s journey forward. Collaborations with industry giants like FrieslandCampina and Umami Bioworks drive innovation in food production.
By co-developing and scaling up the production of essential ingredients through fermentation methodologies, Triplebar is reshaping the future of nutrition.
With the recent funding injection, Triplebar has had a significant global impact. The company’s innovative approach to solving fundamental problems in food and healthcare aligns with the growing demand for sustainable and ethical solutions.
As Triplebar continues to refine and expand its product portfolio, the ripple effects of its innovations will transform the global food and biopharmaceutical industries. Triplebar’s visionary approach to revolutionizing traditional industries marks a significant milestone in the quest for sustainable and ethical solutions.
- Commons Clinic Secures $19.5M Series A Funding to Improve Specialty Healthcare
- Joywell Foods raises $25 million in Series B funding
- Corporate client food ordering platform, Sharebite raises $39 million
- Preply’s AI-powered language learning platform raises $70M in Series C funding
- Precision Medicine Pioneer Triveni Bio Secures $92M Series A Funding